T L Berents1,2, K C Lødrup Carlsen1,3, P Mowinckel3, L Sandvik1,4,5, H O Skjerven1,3, L B Rolfsjord1,6, B Kvenshagen7, J O G Hunderi1,3,7, M Bradley8, A Lieden8, K-H Carlsen1,3, P M Thorsby1,9, P Gjersvik1,2. 1. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2. Department of Dermatology, Oslo University Hospital, Oslo, Norway. 3. Department of Pediatrics, Oslo University Hospital, Oslo, Norway. 4. Department of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. 5. University of Oslo, Oslo, Norway. 6. Department of Pediatrics, Elverum Hospital, Elverum, Norway. 7. Department of Pediatrics, Østfold Hospital, Fredrikstad, Norway. 8. Department of Molecular Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden. 9. Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: Epidemiological data and the effect of sun exposure on atopic eczema (AE) suggest that vitamin D (vitD) may be involved in the pathogenesis. OBJECTIVES: To investigate if vitD levels were associated with the presence or severity of AE in the first 2 years of life in children living in south-east Norway. METHODS: Infants, recruited to a clinical trial on acute bronchiolitis (n = 404) and from the general population (n = 240), were examined at 1-13 months (first visit) and at 2 years of age (second visit). Caregivers were interviewed using a structured questionnaire. AE was diagnosed clinically, based on well-established criteria. Disease severity was assessed using the SCORing Atopic Dermatitis index. Blood samples were taken for vitD measurements, using liquid chromatography-tandem mass spectrometry and for common filaggrin mutation analyses. Complete data on AE and vitD were available in 596 and 449 children at the first and second visit, respectively. RESULTS: Atopic eczema was diagnosed in 67 children (11%) at the first visit and in 103 children (23%) at the second. Mean vitD levels were 58·2 nmol L(-1) at the first visit and 66·9 nmol L(-1) at the second. Using vitD level tertiles in multivariate regression analysis, there was no association between vitD levels and AE at either visit, regardless of filaggrin mutation. In children without AE at the first visit, vitD levels did not predict AE at the second. CONCLUSIONS: In this cohort of young children in Norway, we found no association between vitD levels and the presence or severity of AE.
BACKGROUND: Epidemiological data and the effect of sun exposure on atopic eczema (AE) suggest that vitamin D (vitD) may be involved in the pathogenesis. OBJECTIVES: To investigate if vitD levels were associated with the presence or severity of AE in the first 2 years of life in children living in south-east Norway. METHODS:Infants, recruited to a clinical trial on acute bronchiolitis (n = 404) and from the general population (n = 240), were examined at 1-13 months (first visit) and at 2 years of age (second visit). Caregivers were interviewed using a structured questionnaire. AE was diagnosed clinically, based on well-established criteria. Disease severity was assessed using the SCORing Atopic Dermatitis index. Blood samples were taken for vitD measurements, using liquid chromatography-tandem mass spectrometry and for common filaggrin mutation analyses. Complete data on AE and vitD were available in 596 and 449 children at the first and second visit, respectively. RESULTS:Atopic eczema was diagnosed in 67 children (11%) at the first visit and in 103 children (23%) at the second. Mean vitD levels were 58·2 nmol L(-1) at the first visit and 66·9 nmol L(-1) at the second. Using vitD level tertiles in multivariate regression analysis, there was no association between vitD levels and AE at either visit, regardless of filaggrin mutation. In children without AE at the first visit, vitD levels did not predict AE at the second. CONCLUSIONS: In this cohort of young children in Norway, we found no association between vitD levels and the presence or severity of AE.
Authors: H Blakeway; V Van-de-Velde; V B Allen; G Kravvas; L Palla; M J Page; C Flohr; R B Weller; A D Irvine; T McPherson; A Roberts; H C Williams; N Reynolds; S J Brown; L Paternoster; S M Langan Journal: Br J Dermatol Date: 2020-02-11 Impact factor: 9.302